This trial is active, not recruiting.

Condition pulmonary hypertension
Treatment right heart catheterization
Sponsor Assistance Publique - Hôpitaux de Paris
Start date January 2011
End date December 2015
Trial size 200 participants
Trial identifier NCT01185730, AOM 09065


The objective of this clinical research is to analyze the survival of a cohort of patients newly diagnosed (incident cases) with idiopathic PAH, familial or associated with the use of anorectics (isolated pulmonary vascular disease without comorbidity) and identify prognostic factors using a dynamic model for predicting survival, including prognostic factors evaluated repeatedly at pre-specified periods during follow-up. In a second step, the investigators define using this model combinations of parameters to better define the therapeutic goals in PAH (functional class, exercise testing, hemodynamic, echocardiographic variables, biological parameters).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose prevention
cohort of patients with pulmonary hypertension
right heart catheterization
all patients of the all centers will have Right Heart Catheterization at the diagnosis

Primary Outcomes

death frequency
time frame: 12 months

Secondary Outcomes

death frequency
time frame: Evolution between baseline assessment and follow-up.

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria: - Man or woman aged over 18 years - With pulmonary arterial hypertension (PAH) idiopathic, hereditary or associated with the use of anorectics, newly diagnosed (less than 6 months) whose diagnosis was made by cardiac catheterization finding a mean pulmonary arterial pressure (mPAP)> 25 mm Hg at rest or> 30 mm Hg during exercise, with a pressure pulmonary artery occlusion (PAOP) ≤ 15 mm Hg, - Has given his free and informed consent. Exclusion criteria: - Minor (age <18 years) - PAH patients whose diagnosis was there more than 6 months (prevalent cases), - Patient with PAH associated with concomitant disease (autoimmune disease, portal hypertension, HIV infection, congenital heart disease, schistosomiasis, chronic hemolytic anemia) - Patient with veno-occlusive disease and / or pulmonary capillary hemangiomatosis suspected or documented - Patients with pulmonary hypertension associated with left heart (pulmonary hypertension post-capillary) - Patients with pulmonary hypertension associated with respiratory disease (chronic obstructive pulmonary disease, pulmonary fibrosis, sleep apnea syndrome Sleep) - Patients with pulmonary hypertension post-embolic chronic - Patient with pulmonary hypertension associated with sarcoidosis, histiocytosis X, a Lymphangioleiomyomatosis to mediastinal fibrosis, - Adults protected - Pregnant or lactating - Persons deprived of liberty - Persons in emergency situations, - Persons who refused or unable to give informed consent. - No affiliation to a social security scheme (beneficiary or beneficiary)

Additional Information

Official title Evaluation of Prognostic Factors and Therapeutic Targets in Pulmonary Arterial Hypertension
Principal investigator Olivier SITBON, MD, PhD
Description Pulmonary arterial hypertension (PAH) is a rare disease characterized by an intense proliferation of pulmonary arterial wall causing increased progressive pulmonary vascular resistance, leading to right heart failure and death. Established prognostic factors at diagnosis were identified 20 years ago at a time when there is no specific treatment for describing the natural history of disease. Over the last 10 years, new therapeutic classes (similar to prostacyclin, antagonists of endothelin receptors, inhibitors of phosphodiesterase 5) have been developed and improved symptoms, exercise capacity, and hemodynamics in patients with PAH. With the availability of these new molecules, the clinician is now faced with difficult treatment decisions regarding the choice of initial treatment and the need for road treatments combined during evolution. Therapeutic purpose and effect of these different therapeutic strategies on the long-term survival remain poorly understood. If it has been clearly demonstrated that clinical parameters (NYHA functional class), functional (test 6-minute walk) and hemodynamic (cardiac output and pulmonary vascular resistance) measured before initiation of treatment have a major role in determining the prognosis, with the contribution of new molecules is important to evaluate the prognostic value of changes in these factors during follow-up under specific treatment. At the baseline assessment, including repeat cardiac catheterization rights, it is also important to evaluate other prognostic criteria substitution, including methods of noninvasive evaluation (echocardiography, biomarkers).
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris.